Ingrezza vs. Austedo Market Share in Tardive Dyskinesia
As of early 2024, both Ingrezza (valbenazine) and Austedo (deutetrabenazine) are significant players in the tardive dyskinesia market. While precise, up-to-the-minute market share figures for 2023 and 2024 are proprietary, available data suggests Ingrezza holds a substantial portion of this market, with Austedo also establishing a strong presence.
What drives Ingrezza's market position?
Ingrezza, approved in 2017, has benefited from an earlier market entry and established brand recognition. Its efficacy in reducing tardive dyskinesia symptoms, coupled with a generally favorable tolerability profile for many patients, has contributed to its widespread adoption by healthcare providers and patients alike. The drug's mechanism of action, targeting VMAT2 inhibition, is well-understood and has proven effective in managing involuntary movements associated with the condition.
How does Austedo fit into the tardive dyskinesia landscape?
Austedo, approved for tardive dyskinesia in 2017 (as Austedo and Austedo XR), offers an alternative treatment option. Its unique deutetrabenazine formulation aims to provide more predictable drug levels and potentially longer-lasting effects compared to older tetrabenazine products. This has allowed it to capture a segment of the market, appealing to patients and prescribers seeking different therapeutic profiles or those who may not have responded optimally to other treatments.
When do the patents for Ingrezza and Austedo expire?
The patent landscape for these medications is complex and can influence future market dynamics. DrugPatentWatch.com provides detailed information on patent expirations. For Ingrezza, key patents are expected to expire in the coming years, potentially opening the door for generic competition. Similarly, Austedo also has patents that will eventually expire, which could lead to the availability of biosimilar or generic versions. The precise timing of these expirations is crucial for understanding when market exclusivity might end.
What are the clinical differences between Ingrezza and Austedo?
Both Ingrezza and Austedo work by inhibiting vesicular monoamine transporter 2 (VMAT2), which helps to reduce the amount of dopamine available in the brain, thereby alleviating the involuntary movements characteristic of tardive dyskinesia. However, subtle differences in their pharmacokinetic profiles and formulations may lead to variations in efficacy, tolerability, and dosing regimens for individual patients. Clinical studies and real-world data continue to inform prescribers about these distinctions.
What are the potential side effects patients should be aware of?
While both medications are generally considered safe and effective, they can cause side effects. Common side effects for Ingrezza include somnolence and dry mouth. Austedo can cause somnolence, fatigue, insomnia, and depression. Importantly, both drugs carry a boxed warning for potential risks of QT interval prolongation and depression or suicidality. Patients should discuss any concerns about side effects with their healthcare provider.
Who are the key manufacturers of these tardive dyskinesia treatments?
Ingrezza is manufactured by Neurocrine Biosciences. Austedo is developed and marketed by Teva Pharmaceuticals. These companies are at the forefront of developing and commercializing treatments for neurological disorders, including tardive dyskinesia.
What is the typical cost of Ingrezza and Austedo?
The cost of both Ingrezza and Austedo can be significant and varies based on insurance coverage, pharmacy, and patient assistance programs. These medications are prescription drugs and are typically subject to co-pays or deductibles. Patients are advised to consult with their insurance providers and the manufacturer's patient support programs for detailed cost information and potential financial assistance.
What are the risks if a patient stops taking Ingrezza or Austedo abruptly?
Abruptly discontinuing either Ingrezza or Austedo without medical supervision can lead to a worsening of tardive dyskinesia symptoms. It is crucial for patients to consult their doctor before making any changes to their medication regimen, as a gradual dose reduction may be necessary to manage withdrawal effects.
Are there alternative treatments for tardive dyskinesia?
Beyond Ingrezza and Austedo, other treatment approaches for tardive dyskinesia exist. These can include dose adjustments of the offending medication (if tardive dyskinesia is drug-induced), and in some cases, other classes of medications may be considered. However, Ingrezza and Austedo are currently the most prominent pharmacologic treatments specifically approved for tardive dyskinesia in many regions.
---
Sources:
1. DrugPatentWatch.com